Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Which of the following statements represents the most clinically significant aspect of drug metabolism?

Most common enzyme involved is CYP 3A4/5. ***Most common enzyme involved is Cyp 3A4/5*** - CYP3A4/5 is the **most abundant and clinically significant** cytochrome P450 enzyme, responsible for metabolizing approximately **50% of all clinically used drugs**. - Its widespread involvement means variations in its activity (due to **genetics, drug interactions, or disease**) have a major impact on drug efficacy and toxicity. *Glucuronidation is a phase II reaction* - While correct that glucuronidation is a **Phase II metabolic reaction**, this statement describes a biochemical classification rather than a clinically significant aspect compared to the involvement of CYP3A4/5. - Phase II reactions generally involve **conjugation** to increase water solubility and facilitate excretion, but they do not collectively account for as many drug interactions as CYP3A4/5 alone. *Reduction is a phase I reaction* - This statement is factually correct as **reduction** is indeed a **Phase I metabolic reaction**. - However, it represents a generic classification of a metabolic pathway and doesn't highlight the specific clinical importance or prevalence of a particular enzyme or reaction in drug metabolism. *Cytochrome P450 is involved in phase I reactions* - This is true; the **cytochrome P450 system** is the primary enzyme system for **Phase I metabolism**, which introduces or exposes polar groups to make drugs more reactive. - While fundamentally important, this statement is too broad; it does not specify the most clinically significant *aspect* or *enzyme* within the P450 system compared to directly identifying CYP3A4/5.

Q: Among the following statins, which has the longest half-life?

Rosuvastatin. **Rosuvastatin** - **Rosuvastatin** has the longest half-life among the commonly used statins, approximately **19 hours**, allowing for consistent lipid-lowering effects. - Its prolonged presence in the body contributes to its effectiveness in reducing **LDL-C** at lower doses. *Pravastatin* - **Pravastatin** has a relatively short half-life of about **1.8 hours**, requiring daily dosing to maintain therapeutic concentrations. - Its hydrophilic nature means it is less likely to penetrate non-hepatic tissues, potentially reducing extrahepatic side effects. *Simvastatin* - **Simvastatin** has a short half-life of about **3 hours**, necessitating daily administration. - It is a **prodrug** that requires hepatic activation to its active beta-hydroxy acid form. *Lovastatin* - **Lovastatin** also has a short half-life, around **3 hours**, and is a **prodrug** like simvastatin. - It is often recommended to be taken in the evening due to the diurnal rhythm of cholesterol synthesis.

Q: Regarding the concepts of efficacy and potency of a drug, which of the following statements is FALSE?

ED50 of the drug corresponds to efficacy. ***ED50 of the drug corresponds to efficacy*** - **ED50** (median effective dose) is the dose at which 50% of individuals exhibit the specified effect; it quantifies **potency**, not efficacy. - **Efficacy** refers to the maximum effect a drug can produce, while potency refers to the amount of drug needed to produce an effect. *In a clinical setup, efficacy is more important than potency* - **Efficacy** determines the maximal therapeutic benefit a drug can achieve for a patient, making it crucial for clinical outcomes. - While **potency** influences the dose required, a highly potent drug that is not very efficacious may not be clinically useful. *Drugs that produce a similar pharmacological effect can have different levels of efficacy* - Two drugs might act on the same receptor but elicit different maximal responses, indicating varying **efficacy**. - For example, a **partial agonist** and **full agonist** interacting with the same receptor will have different efficacies. *In the log dose response curve, the height of the curve corresponds with efficacy* - The **maximal response** or plateau of the dose-response curve represents the **efficacy** of a drug. - A higher plateau on the curve indicates a drug with greater intrinsic activity achieving a larger effect.

Q: Volume of distribution of a drug is 500 ml and target concentration of drug in blood is 5 g/L. 20% of administered drug is reached to systemic circulation. What will be the loading dose of that drug -

12.5 gm. ***12.5 gm*** - The formula for loading dose (LD) is: LD = (Target Concentration × Volume of Distribution) / Bioavailability. - Given: Target Concentration = 5 g/L, Volume of Distribution = 500 mL = 0.5 L, Bioavailability = 20% = 0.2. - So, LD = (5 g/L × 0.5 L) / 0.2 = 2.5 g / 0.2 = **12.5 g**. *1 gm* - This value would be obtained if the target concentration was 2 g/L with 100% bioavailability, or if the calculation incorrectly handled the volume or bioavailability factor. - It does not account for the specified **bioavailability of 20%** or the given target concentration and volume of distribution. *5 gm* - This result would be obtained if the bioavailability was assumed to be 50% (LD = 2.5 g / 0.5 = 5 g), or if the volume of distribution was incorrectly used in the calculation. - This option does not correctly factor in the **20% bioavailability** of the administered drug. *25 gm* - This value would result from mistakes such as dividing by bioavailability of 10% instead of 20% (LD = 2.5 g / 0.1 = 25 g), or by multiplying bioavailability instead of dividing by it. - This answer significantly **overestimates** the required dose, which could lead to drug toxicity.

Q: Where does the oxidation of drugs mainly take place?

Smooth ER. **Smooth ER** - The **smooth endoplasmic reticulum (SER)** is rich in enzymes, particularly the **cytochrome P450 system**, which is primarily responsible for phase I **oxidation reactions** of many drugs and xenobiotics [1]. - These oxidative reactions typically **increase the polarity** of drugs, making them easier to excrete [1]. *Nucleus* - The nucleus primarily contains the cell's **genetic material** (DNA) and is involved in **gene expression** and replication. - It does not contain the necessary enzymatic machinery for the major oxidative metabolism of drugs. *Rough ER* - The **rough endoplasmic reticulum (RER)** is characterized by the presence of **ribosomes** and is mainly involved in the **synthesis, folding, modification, and transport of proteins** destined for secretion or insertion into membranes [2]. - While it plays a role in protein synthesis, it is not the primary site for drug oxidation. *Cytoplasm* - The cytoplasm contains various organelles and is the site of many metabolic pathways, including **glycolysis** and some **phase II drug metabolism** (e.g., glucuronidation, sulfation) [1]. - However, the bulk of phase I **oxidative drug metabolism** does not occur in the general cytoplasm but rather within the smooth ER due to the concentration of relevant enzymes there [1].

Q: Fastest receptor mediated action is through?

Intrinsic ion channels. ***Intrinsic ion channels*** - Receptors that are also **ion channels** (ligand-gated ion channels) allow direct and rapid ion flow across the membrane upon ligand binding, leading to immediate changes in membrane potential. - This direct mechanism bypasses complex intracellular signaling cascades, resulting in the **fastest cellular response** compared to other receptor types. *Cell surface receptors* - This is a broad category that includes **G protein-coupled receptors** and **receptor tyrosine kinases**, which typically involve more complex and slower signaling pathways. - While located on the cell surface, not all receptors in this category mediate action as quickly as intrinsic ion channels. *Receptor tyrosine kinases* - These receptors initiate signaling by **phosphorylating tyrosine residues** on target proteins, triggering a cascade of intracellular events that take time to manifest. - Their action involves **multiple phosphorylation steps** and protein interactions, making their response slower compared to direct ion channels. *Intracellular receptors* - These receptors, such as **steroid hormone receptors**, are located in the cytoplasm or nucleus and require their ligands to diffuse across the cell membrane. - The activated receptor then typically translocates to the nucleus to regulate gene transcription, a process that is much **slower** due to gene expression and protein synthesis.

Q: Which of the following statements about oral iron preparations is correct?

Different preparations have different bioavailability. ***Different preparations have different bioavailability*** - The **bioavailability** of oral iron preparations varies depending on the specific salt used, its formulation, and the presence of absorption enhancers or inhibitors. - This difference in absorption impacts the required dose and efficacy in treating **iron deficiency anemia**. *Most commonly used preparation is ferrous gluconate* - **Ferrous sulfate** is the most commonly prescribed and cost-effective oral iron preparation due to its high iron content and good bioavailability. - While ferrous gluconate is used, its iron content is lower than ferrous sulfate, making it less frequently the primary choice. *Ferrous fumarate is most efficient* - While **ferrous fumarate** has a high elemental iron content, its efficiency doesn't necessarily surpass that of ferrous sulfate or other preparations when considering factors like bioavailability and side effect profile. - **Ferrous sulfate** is often considered efficient due to its balance of elemental iron content, bioavailability, and cost-effectiveness. *Ferric preparations are more effective* - **Ferrous (Fe2+)** iron is generally better absorbed than **ferric (Fe3+)** iron, as ferric iron needs to be reduced to its ferrous form before absorption. - Unless specifically formulated for enhanced absorption (e.g., ferric maltol), ferric preparations are typically *less* effective for initial iron repletion.

Q: Which of the following pairs are considered physiological antagonists in pharmacology?

Histamine and Adrenaline. ***Histamine and Adrenaline*** - **Physiological antagonism** occurs when two drugs produce opposite effects by acting on different receptors or pathways. - **Histamine** causes bronchoconstriction and vasodilation, while **adrenaline** causes bronchodilation and vasoconstriction, counteracting each other's effects through different mechanisms. *Adrenaline and Isoprenaline* - Both **adrenaline** and **isoprenaline** are **adrenergic agonists** that produce similar physiological effects, primarily through beta-adrenergic receptor activation. - They are not physiological antagonists but rather have **synergistic** or similar pharmacological actions. *Isoprenaline and Propranolol* - **Isoprenaline** is a **beta-adrenergic agonist**, while **propranolol** is a **beta-adrenergic antagonist**. - This is an example of **pharmacological antagonism (receptor antagonism)**, where one drug blocks the effect of another at the same receptor site, rather than physiological antagonism.

Q: Which of the following statements about transdermal drug delivery systems is false?

Good option in emergency situations. ***Option D: Good option in emergency situations*** - Transdermal drug delivery systems have a **slow onset of action** due to the time required for drug absorption through the skin layers. - This characteristic makes them **unsuitable for emergency situations** where immediate therapeutic effect is critical for patient stabilization. - Emergency situations require drugs with **rapid onset** via routes like intravenous, intramuscular, or sublingual administration. *Option A: Applied to chest, abdomen and back* - This statement is TRUE. Transdermal patches are commonly applied to areas with **good blood supply** and **minimal hair**, such as the chest, abdomen, and back. - These sites provide a relatively **large surface area** for absorption and allow for discreet placement with consistent drug delivery. *Option B: Drug is delivered at a constant rate* - This statement is TRUE. A primary advantage of transdermal systems is their ability to provide **controlled and sustained release** of medication over an extended period (typically 24-72 hours). - This constant delivery helps maintain **steady-state therapeutic drug levels** and minimizes fluctuations in plasma concentration, reducing side effects. *Option C: Fentanyl is used* - This statement is TRUE. **Fentanyl** is a potent opioid commonly delivered via transdermal patches for **chronic pain management**. - Its transdermal formulation ensures **continuous analgesia** over 72 hours and bypasses first-pass metabolism, improving bioavailability and making it effective for long-term use.

Q: Which of the following drug combinations demonstrates receptor level antagonism?

Isoprenaline (agonist) and Propranolol (antagonist). ***Isoprenaline (agonist) and Propranolol (antagonist)*** - **Propranolol** is a **beta-adrenergic receptor antagonist**, meaning it binds to and blocks beta-adrenergic receptors. - **Isoprenaline** is a **beta-adrenergic receptor agonist**, meaning it activates these same receptors. Their combined action demonstrates **receptor-level antagonism** as propranolol prevents isoprenaline from binding and eliciting its effect. *Histamine and Adrenaline* - This combination illustrates **physiological antagonism**, where two drugs produce opposite effects through different mechanisms and different receptors. - **Adrenaline** causes bronchodilation and vasoconstriction via adrenergic receptors, counteracting the effects of **histamine** (e.g., bronchoconstriction, vasodilation) which acts on histamine receptors. *Adrenaline and Isoprenaline* - Both **adrenaline** and **isoprenaline** are **agonists** of adrenergic receptors, specifically beta-adrenergic receptors. - They would produce similar effects (e.g., increased heart rate, bronchodilation) rather than opposing each other at the receptor level. *None of the options* - This is incorrect because **Isoprenaline and Propranolol** is a valid example of receptor-level antagonism, making this option unnecessary.

Question 1

Which of the following statements represents the most clinically significant aspect of drug metabolism?

Accepted Answer

Most common enzyme involved is CYP 3A4/5

Answer

Glucuronidation is a phase II reaction

Answer

Reduction is a phase I reaction

Answer

Cytochrome P450 is involved in phase I reactions

Question 2

Among the following statins, which has the longest half-life?

Accepted Answer

Rosuvastatin

Answer

Pravastatin

Answer

Simvastatin

Answer

Lovastatin

Question 3

Regarding the concepts of efficacy and potency of a drug, which of the following statements is FALSE?

Accepted Answer

ED50 of the drug corresponds to efficacy

Answer

Drugs that produce a similar pharmacological effect can have different levels of efficacy

Answer

In a clinical setup, efficacy is more important than potency

Answer

In the log dose response curve, the height of the curve corresponds with efficacy

Question 4

Volume of distribution of a drug is 500 ml and target concentration of drug in blood is 5 g/L. 20% of administered drug is reached to systemic circulation. What will be the loading dose of that drug -

Accepted Answer

12.5 gm

Answer

1 gm

Answer

5 gm

Answer

25 gm

Question 5

Where does the oxidation of drugs mainly take place?

Accepted Answer

Smooth ER

Answer

Rough ER

Answer

Cytoplasm

Answer

Nucleus

Question 6

Fastest receptor mediated action is through?

Accepted Answer

Intrinsic ion channels

Answer

Intracellular receptors

Answer

Cell surface receptors

Answer

Receptor tyrosine kinases

Question 7

Which of the following statements about oral iron preparations is correct?

Accepted Answer

Different preparations have different bioavailability

Answer

Most commonly used preparation is ferrous gluconate

Answer

Ferrous fumarate is most efficient

Answer

Ferric preparations are more effective

Question 8

Which of the following pairs are considered physiological antagonists in pharmacology?

Accepted Answer

Histamine and Adrenaline

Answer

Adrenaline and Isoprenaline

Answer

Isoprenaline and Propranolol

Answer

All of the options

Question 9

Which of the following statements about transdermal drug delivery systems is false?

Accepted Answer

Good option in emergency situations

Answer

Applied to chest, abdomen and back

Answer

Drug is delivered at a constant rate

Answer

Fentanyl is used

Question 10

Which of the following drug combinations demonstrates receptor level antagonism?

Accepted Answer

Isoprenaline (agonist) and Propranolol (antagonist)

Answer

Histamine and Adrenaline

Answer

Adrenaline and Isoprenaline

Answer

None of the options

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?